Cargando…
UPLC-MS/MS Based Identification and Quantification of a Novel Dual Orexin Receptor Antagonist in Plasma Samples by Validated SWGTOX Guidelines
Lemborexant (LEM) is a novel dual orexin receptor antagonist (DORA), recently approved for the treatment of insomnia. As with other DORAs, LEM has potential of abuse and therefore placed in Schedule IV class by the United States Drug Enforcement Administration (USDEA). In this study, a sensitive and...
Autores principales: | Iqbal, Muzaffar, Alshememry, Abdullah, Imam, Faisal, Kalam, Mohd Abul, Akhtar, Ali, Ali, Essam A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959124/ https://www.ncbi.nlm.nih.gov/pubmed/36850983 http://dx.doi.org/10.3390/toxics11020109 |
Ejemplares similares
-
UPLC–MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats
por: Ezzeldin, Essam, et al.
Publicado: (2020) -
Eco-Friendly UPLC–MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats
por: Ezzeldin, Essam, et al.
Publicado: (2021) -
Eco-Friendly, Simple, Fast, and Sensitive UPLC-MS/MS Method for Determination of Pexidartinib in Plasma and Its Application to Metabolic Stability
por: Ezzeldin, Essam, et al.
Publicado: (2022) -
Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate
por: Kalam, Mohd Abul, et al.
Publicado: (2022) -
Fabrication and Characterization of Tedizolid Phosphate Nanocrystals for Topical Ocular Application: Improved Solubilization and In Vitro Drug Release
por: Kalam, Mohd Abul, et al.
Publicado: (2022)